Climb Bio (CLYM) Retained Earnings (2021 - 2026)
Climb Bio's (CLYM) quarterly Retained Earnings came in at $157000.0 in Q1 2026, down 45.1% YoY from $286000.0 in Q1 2025, and up 100.05% on a QoQ basis from -$289.7 million in Q4 2025.
Climb Bio (CLYM) Retained Earnings (2021 - 2026) Analysis & Trends
Climb Bio (CLYM) has 6 years of Retained Earnings data on file, last reported at $157000.0 in Q1 2026.
- Quarterly Retained Earnings fell 45.1% year-over-year to $157000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157000.0 (down 45.1% YoY) and the FY2025 annual result came in at -$289.7 million, down 1259782.61% from the prior year.
- Retained Earnings grew to $157000.0 in Q1 2026, from -$289.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $469000.0 in Q3 2025 to a low of -$289.7 million in Q4 2025.
- A 5-year average of -$67.5 million and a median of -$358000.0 in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings plunged 2013172.73% — and 2025, when it soared 100.21%.
- Tracing CLYM's Retained Earnings over 5 years: stood at -$358000.0 in 2022, then sank by 43469.55% to -$156.0 million in 2023, then soared by 100.01% to $23000.0 in 2024, then slumped by 1259782.61% to -$289.7 million in 2025, then jumped by 100.05% to $157000.0 in 2026.
- The last three Retained Earnings figures came in at $157000.0 (Q1 2026), -$289.7 million (Q4 2025), and $469000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | -316.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -316.95 Mn |
| Mar 31, 2026 | 157,000.00 |
| Dec 31, 2025 | -289.73 Mn |
| Sep 30, 2025 | 469,000.00 |
| Jun 30, 2025 | 318,000.00 |
| Mar 31, 2025 | 286,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | -221.46 Mn |
| Dec 31, 2023 | -155.98 Mn |
| Sep 30, 2023 | -11,000.00 |
| Jun 30, 2023 | -35,000.00 |
| Mar 31, 2023 | -143.20 Mn |
| Dec 31, 2022 | -358,000.00 |
| Sep 30, 2022 | -113.10 Mn |
| Jun 30, 2022 | -604,000.00 |
| Mar 31, 2022 | -88.80 Mn |
| Dec 31, 2021 | -75.62 Mn |
| Sep 30, 2021 | -65.10 Mn |
| Jun 30, 2021 | -55.46 Mn |